Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
- Summary
- The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.
- Short title
- Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
- Official title
- A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors With MET Overexpression and/or Amplification
- Control arm
- Active comparator
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Completion date
- 2027-10-30
- First posted
- 2025-04-27
- Registry last updated
- 2025-09-08
- Primary completion date
- 2027-04-30
- Start date
- 2025-06-04
- Participants
- Participant count basis
- Estimated
- Planned participants
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT06947291
- ClinicalTrials.gov ID
- NCT06947291
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Parallel groups
- Purpose
- Treatment
- Masking
- No masking
Dose escalation and cohort expansion phase: The occurrence and frequency of DLT (Dose-Limiting Toxicity)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: the occurrence and frequency of AE (Adverse Events) and SAE (Serious Adverse Events) (in accordance with NCI-CTCAE 5.0)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Recommended Phase 2 Dose (RP2D) for the combination therapy.
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept phase: Objective Response Rate (ORR) evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria.
Timeframe: Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Disease Control Rate (DCR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Duration of Response (DoR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Progression-Free Survival (PFS)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Overall Survival (OS)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria: Disease Control Rate (DCR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria:Duration of Response (DoR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria: Progression-Free Survival (PFS)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study： Evaluated by the Investigator according to the RECIST 1.1 criteria: Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Investigator according to the RECIST 1.1 criteria: Disease Control Rate (DCR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Investigator according to the RECIST 1.1 criteria: Duration of Response (DoR)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study： Evaluated by the Investigator according to the RECIST 1.1 criteria: Progression-Free Survival (PFS)
Timeframe: Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study： Overall Survival (OS)
Timeframe: Up to approximately 24 months after the first patient is enrolled
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Healthy volunteers
- No
- 1. Patients who are able to understand and voluntarily sign the written ICF;
- 2. Male or female patients aged ≥ 18 years (inclusive);
- 3. Patients with advanced solid tumors diagnosed by pathology or cytology;
- 4. Patients with a past medical history showing either negative or positive Her-2 expression can be enrolled. For those with unknown Her-2 expression, the Her-2 status needs to be determined before enrollment. For patients with positive Her-2 expression, their previous treatments should include anti-Her-2 drug therapy.
- 5. Overexpression and/or amplification of MET in tumor tissue specimens/blood samples confirmed by the central laboratory.
- 6. There are measurable lesions or non-measurable but evaluable lesions according to RECIST v1.1.
- 7. The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score is 0 or 1.
- 8. The expected survival time is ≥ 3 months.
- 9. The functions of major organs and bone marrow meet the criteria.
- 1. Patients with prior treatment with targeted MET drugs;
- 2. Previous treatments included docetaxel;
- 3. Patients with meningeal metastases, spinal cord compression, symptomatic or progressive brain metastases are not eligible for enrollment.
- 4. Known hypersensitivity or intolerable conditions to any component of the drugs in the study protocol or their excipients.
- 5. According to NCI-CTCAE 5.0, adverse events caused by previous anti-tumor treatment have not recovered to ≤ Grade 1 (excluding toxicities such as Grade 2 alopecia which are judged by the investigator to pose no safety risk).
- 6. Any severe and/or uncontrolled co-existing diseases that may prevent the patient from participating in the study.
- 7. Female patients who are lactating or pregnant; Women of childbearing potential with a positive blood pregnancy test result within 7 days before trial enrollment. Lactating women can participate in this study if they stop breastfeeding, but they must not resume breastfeeding during and after the completion of the study treatment.
- 8. Any male or female patient of childbearing potential who refuses to use a highly effective contraceptive method throughout the trial period and within 6 months after the last administration.
- 9. Those who are unwilling or unable to comply with the study procedures and requirements, or those who, in the judgment of the investigator, are not suitable for participating in this study.
- Zhejiang Cancer HospitalHangzhou, ChinaRecruiting
Related records
Drugs (2)
Lead sponsors (1)
Conditions (1)
- Gastroesophageal junction adenocarcinoma Primary condition